RCI Names Dr. Mitchell Abrahamsen as EVP & CCO
Recombinetics (RCI) announced that Dr. Mitchell Abrahamsen has joined RCI as Executive Vice President and Chief Commercial Officer. Dr. Abrahamsen will lead product and business development efforts for RCI and its subsidiaries that are commercializing gene-edited animal models for biomedical and agricultural use, Acceligen and Surrogen. Abrahamsen will also continue to [...]
4 Ways This Revolutionary Gene-Editing Tool Could Change the World
Recombinetics and its subsidiaries are working on #1, #2, and #3 in this NBC News article on CRISPR.